BrainQ builds a cloud-connected home therapy system that uses EEG-informed, low-intensity magnetic field (ELF-EMF) stimulation to target stroke-affected neural networks and accelerate neuroplastic recovery. The product is a whole-brain cylindrical headset paired with a back/hip pack, a tablet app, and a telemedicine/caregiver workflow for at‑home use. Treatment sessions last about an hour during which patients perform exercises while the headset streams EEG data to BrainQ’s cloud to generate personalized stimulation parameters. A small 25-patient study reported that 92% of treated patients saw major improvements over therapy alone and 80% achieved what the article described as recovery, results that supported FDA Breakthrough Device designation. The Breakthrough status also confers qualification for Medicare coverage and could enable shipment within a year or two. BrainQ raised $40 million to advance commercialization and run a larger clinical study. BrainQ develops personalized electromagnetic treatment protocols for stroke victims and patients with spinal cord injuries by analyzing patients' brainwaves. The company uses AI and claims to own one of the largest BCI-based EEG databases for motor tasks, which it says enables tailored therapies. At the time of the article, BrainQ was running two human clinical trials for stroke patients in Israel and working with Google’s Launchpad Accelerator. The team includes former members of Israeli elite intelligence units and academics with AI and neuroscience backgrounds. Financially, BrainQ announced a $5.3 million financing on top of a prior $3.5 million raise. The company says it plans to push its technology, expand operations, and position itself as a leader in BCI-based precision medicine. BrainQ develops a non-surgically embedded EEG system to gather neural data and aid recovery for stroke and spinal cord injury patients. The company is conducting two human clinical trials for stroke patients in Israel and must gain FDA approval before selling services in the U.S. A spokesperson said BrainQ will likely enter other markets first while awaiting U.S. regulatory clearance and hopes to be available in the U.S. by 2020. The startup has plans to expand into Alzheimer’s research and potentially children’s syndromes. BrainQ faces competition from implant-focused firms like Kernel and Neuralink as well as EEG-based competitors such as NeuroLutions and NeuroPace. Google’s Launchpad Studio worked with the company, and BrainQ has presented clinical findings to the World Congress of Neuro Rehabilitation. Financially, BrainQ has raised about $3.5 million to date from various Israeli investors and angel backers.

Total raised

$49M

Funding rounds

3

Latest round

Equity

Latest activity

Aug 2021